Literature DB >> 2015715

The first international urokinase/warfarin trial in colorectal cancer.

L Daly1.   

Abstract

Three hundred and forty-four patients with operable colorectal adenocarcinoma, Dukes' stage B or C, were entered into a randomized controlled trial of intraoperative and postoperative intravenous urokinase and/or long-term sodium warfarin therapy. The factorial design of the trial allowed evaluation of each therapy separately. Age, sex, Dukes' stage and cancer site were similar in the treatment groups. Using life-table methods, survival and recurrence/metastases free survival were estimated up to 6 years postoperatively. No significant effects of either therapy on these endpoints were found.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2015715     DOI： 10.1007/bf01831705

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN： 0262-0898            Impact factor:   5.150


  12 in total

Review 1.  The significance of the circulating cancer cell.

Authors:  A J Salsbury
Journal:  Cancer Treat Rev       Date:  1975-03       Impact factor: 12.111

2.  Circulating malignant cells and fibrinolysis during resection of colorectal cancer.

Authors:  H White; J D Griffiths
Journal:  Proc R Soc Med       Date:  1976-07

3.  Indirect activation of blood coagulation in colon cancer.

Authors:  M Z Wojtukiewicz; L R Zacharski; V A Memoli; W Kisiel; B J Kudryk; S M Rousseau; D C Stump
Journal:  Thromb Haemost       Date:  1989-12-29       Impact factor: 5.249

4.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

5.  Planning the duration of long-term survival time studies designed for accrual by cohorts.

Authors:  B S Pasternack; H S Gilbert
Journal:  J Chronic Dis       Date:  1971-12

Review 6.  Anticoagulants in the treatment of cancer.

Authors:  P Hilgard; R D Thornes
Journal:  Eur J Cancer       Date:  1976-10       Impact factor: 9.162

7.  Effect of perioperative low-dose heparin administration on the course of colon cancer.

Authors:  F H Kohanna; J Sweeney; S Hussey; L R Zacharski; E W Salzman
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

8.  Prevention of early recurrence of high risk malignant melanoma by coumarin. Irish Melanoma Group.

Authors:  D Thornes; L Daly; G Lynch; H Browne; A Tanner; F Keane; S O'Loughlin; T Corrigan; P Daly; G Edwards
Journal:  Eur J Surg Oncol       Date:  1989-10       Impact factor: 4.424

9.  The influence of heparin and curable resection on the survival of colorectal cancer.

Authors:  S Törngren; A Rieger
Journal:  Acta Chir Scand       Date:  1983

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  6 in total

Review 1.  Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.

Authors:  D L Ornstein; L R Zacharski
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2017-12-29

Review 3.  The impact of warfarin on overall survival in cancer patients.

Authors:  Thita Chiasakul; Jeffrey I Zwicker
Journal:  Thromb Res       Date:  2021-11-14       Impact factor: 10.407

Review 4.  Clinical trials with anticoagulant and antiplatelet therapies.

Authors:  L R Zacharski; K R Meehan; S M Algarra; F A Calvo
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 5.  Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

Authors:  I García-Escobar; C Beato-Zambrano; J Muñoz Langa; E Brozos Vázquez; B Obispo Portero; D Gutiérrez-Abad; A J Muñoz Martín
Journal:  Clin Transl Oncol       Date:  2018-02-22       Impact factor: 3.405

Review 6.  Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms.

Authors:  Javad Sharifi-Rad; Natália Cruz-Martins; Pía López-Jornet; Eduardo Pons-Fuster Lopez; Nidaa Harun; Balakyz Yeskaliyeva; Ahmet Beyatli; Oksana Sytar; Shabnum Shaheen; Farukh Sharopov; Yasaman Taheri; Anca Oana Docea; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-23       Impact factor: 6.543
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.